Literature DB >> 1550087

Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study.

F G Fowkes1, E Housley, R A Riemersma, C C Macintyre, E H Cawood, R J Prescott, C V Ruckley.   

Abstract

The aim was to determine if certain risk factors in the general population are more strongly related to peripheral arterial disease than to ischemic heart disease. Arterial disease in the lower limbs was measured by means of the World Health Organization questionnaire on intermittent claudication, the ankle brachial pressure index, and a reactive hyperemia test in 1,592 men and women aged 55-74 years selected randomly in 1988 from the age-sex registers of 10 general practices in Edinburgh, Scotland. Peripheral arterial disease was strongly related to lifetime cigarette smoking, with additional risks in current and exsmokers of less than 5 years. Multiple regression of risk factors on measures of peripheral arterial disease showed associations with diabetes mellitus (but not impaired glucose tolerance), systolic blood pressure, and serum cholesterol; inverse association with high-density lipoprotein cholesterol; and only univariate association with triglycerides. In multiple logistic regressions of risk factors on six separate indicators of cardiovascular disease, the only consistent difference was that smoking increased the risk of peripheral arterial disease (range of odds ratios, 1.8-5.6) more than heart disease (range of odds ratios, 1.1-1.6). Diabetes mellitus was not a stronger risk factor for peripheral arterial disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1550087     DOI: 10.1093/oxfordjournals.aje.a116294

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  55 in total

1.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Pulse pressure and subclinical peripheral artery disease.

Authors:  P Korhonen; H Kautiainen; P Aarnio
Journal:  J Hum Hypertens       Date:  2013-10-17       Impact factor: 3.012

Review 3.  Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis.

Authors:  Joe F Lau; Mitchell D Weinberg; Jeffrey W Olin
Journal:  Nat Rev Cardiol       Date:  2011-05-31       Impact factor: 32.419

4.  Approach to smoking cessation in the patient with vascular disease.

Authors:  Elizabeth V Ratchford; James H Black
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-04

Review 5.  Peripheral artery disease: epidemiology and global perspectives.

Authors:  F Gerry R Fowkes; Victor Aboyans; Freya J I Fowkes; Mary M McDermott; Uchechukwu K A Sampson; Michael H Criqui
Journal:  Nat Rev Cardiol       Date:  2016-11-17       Impact factor: 32.419

6.  Age, male gender, and atrial fibrillation predict lower extremity amputation or revascularization in patients with peripheral artery diseases: a population-based investigation.

Authors:  Jien-Jiun Chen; Lian-Yu Lin; Chang-Hsing Lee; Chiau-Suong Liau
Journal:  Int J Angiol       Date:  2012-03

Review 7.  The benefits of stopping smoking and the role of nicotine replacement therapy in older patients.

Authors:  S G Gourlay; N L Benowitz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

8.  Mortality following operations for lower extremity peripheral arterial disease.

Authors:  Tracie C Collins; David Nelson; Jasjit S Ahluwalia
Journal:  Vasc Health Risk Manag       Date:  2010-05-06

Review 9.  [Epidemiology and prognosis of peripheral obliterative arteriopathy].

Authors:  R Verhaeghe
Journal:  Drugs       Date:  1998       Impact factor: 9.546

Review 10.  [Quality of life and peripheral obliterative arteriopathy. Perspective for the future].

Authors:  P Priollet
Journal:  Drugs       Date:  1998       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.